Full-Time

Cfc – Customer Facing Colleague

Insights & Execution Associate

Posted on 4/18/2025

Pfizer

Pfizer

10,001+ employees

Develops and manufactures biopharmaceutical products

No salary listed

Mid

Sydney NSW, Australia

Hybrid work location; specific in-office days not mentioned.

Category
Strategy Development
Business Development
Business & Strategy
Required Skills
Marketing
Business Analytics
Data Analysis
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Pfizer referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor’s degree required
  • 3+ years of multi-disciplinary experience with a preference for exposure to business analytics/finance, marketing, engineering, or other quantitative field
  • Proven ability in managing day-to-day planning and operational activities
  • Solid problem-solving, facilitation, and analytical skills
  • Possess a high energy level, sense of urgency, creativity, decisiveness, ability to work hard and well under pressure
  • Strong interpersonal skills
  • Strong proficiency in Microsoft Office Suite
Responsibilities
  • Support delivery of globally consistent Customer Facing Colleague (CFC) Reporting and Stewardship solutions aligned with local market leadership.
  • Partner with other local teams inclusive of Biopharma Operations Partners (BOPs), Incentive compensation and CFC Delivery group and CFC enablement as appropriate to provide the data to support prioritized Field Force initiatives.
  • Partner with global reporting solution product owners to evolve reporting solutions in line with local market needs, working back with local market stakeholders through change management and training as needed.
  • Collaborate with GCA/CFE teams to facilitate CFC related analytics delivery.
  • Ensure the accurate representation of targeting data in operational systems.
  • Identify data and insight needs and help design and execute analytics and research plans, utilizing GCA capabilities such as secondary data analysis and primary market research.
  • Support the effective use of promotional resources through customer analytics, segmentation and targeting, resource allocation, field force sizing, and omnichannel analysis.
  • Connect research and analytics to enable actionable insights and recommendations for commercial leaders.
  • Continuously seek ways to improve by identifying new capabilities, data and tools that provide Pfizer with a competitive advantage.
  • Support the ANZ IIS team in day-to-day TA management, delivering data/insights to help drive commercial decisions.
Desired Qualifications
  • Knowledge of the pharmaceutical industry in Australia
  • Experience with SQL is highly desirable
  • Demonstrated experience in data analytics, data reporting & visualization, and customer analysis
  • Familiarity with artificial intelligence/machine learning (AI/ML) and data science approaches
  • Ability to act as a strategic partner to commercial leadership
  • Capacity to quickly establish relationships of trust and credibility
  • Innovative and agile mindset; self-starter
  • Demonstrated analytics & insights expert
  • Demonstrated business acumen
  • Fluency in English

Pfizer develops and manufactures healthcare products, focusing on medicines and vaccines. The company conducts extensive research to create new treatments, which are then sold to governments, healthcare providers, and patients around the world. Pfizer's products include vaccines, cancer treatments, and other specialized medications. A key aspect of Pfizer's work is its partnership with BioNTech to produce a vaccine for COVID-19, showcasing its role in addressing public health challenges. Unlike many competitors, Pfizer emphasizes not only the development of new drugs but also initiatives to ensure that vaccines reach underserved communities. The company's goal is to continuously expand its range of treatments and improve global health outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Activist investor Starboard Value's $1B stake may drive strategic changes and increase value.
  • Pfizer's investment in Enara Bio strengthens its position in the immunotherapy market.
  • Backing Promise Bio aligns with Pfizer's strategy to enhance its precision medicine portfolio.

What critics are saying

  • Emerging biotech companies like Trimtech and Normunity could impact Pfizer's market share.
  • Slowdown in COVID-19 vaccine demand poses potential revenue challenges for Pfizer.
  • Activist investor involvement may pressure Pfizer to alter business strategies.

What makes Pfizer unique

  • Pfizer's partnership with BioNTech led to a highly effective COVID-19 vaccine.
  • Pfizer invests in AI disease models, enhancing R&D capabilities and drug discovery.
  • Pfizer's focus on precision medicine diversifies its therapeutic areas and strengthens its portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Finsmes
Mar 5th, 2025
Trimtech Therapeutics Raises $31M in Seed Funding

Trimtech Therapeutics, a Cambridge, UK-based biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, raised $31M in Seed funding

Business Wire
Jan 16th, 2025
Normunity Closes $75 Million Series B Financing to Advance Lead Drug Program Into the Clinic and Broaden Pipeline of Novel Anti-Cancer Therapies Targeting Untapped Drug Mechanisms

Normunity, a biotechnology company creating novel anti-cancer therapies, today announced that it has closed a Series B financing for $75 million. The

TechCrunch
Oct 23rd, 2024
Promise Bio exits stealth backed by Pfizer and AstraZeneca | TechCrunch

The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune diseases.

The Wall Street Journal
Oct 7th, 2024
Exclusive | Activist Starboard Value Takes $1 Billion Stake in Pfizer

The drugmaker’s shares have slumped as demand for Covid-19 vaccines and treatments had slowed.

Benzinga
Oct 3rd, 2024
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health InvestorsEnara Bio's EDAPT® platform is

INACTIVE